GleamWall
中文EN

IBRX ImmunityBio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1326110 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY121.2%
TTM net income YoY-218.3%
TTM EPS YoY-158.5%
Revenue 3-yr CAGR589.9%
Net income 3-yr CAGR—

Margins

Gross margin98.8%
Operating margin-150.2%
Net margin-607.8%
FCF margin-162.5%
EBITDA margin-141.1%

Returns

ROE—
ROA-196.7%
ROIC (approx.)—
Asset turnover0.32x

Leverage & solvency

Liabilities / assets288.0%
Debt / equity—
Current ratio4.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.26x
Accruals ratio-145.7%
Payout ratio—
Capex / revenue5.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$113.29M$14.74M
Cost of revenue$753,000$0
Gross profit$112.53M$14.74M
R&D expense—$190.14M
SG&A expense—$168.78M
Operating income-$256.03M-$344.18M
Interest expense$60.89M$114.59M
Pretax income-$351.61M-$413.64M
Income tax-$135,000$0
Net income-$351.40M-$413.56M
EBITDA-$240.50M-$326.63M
EPS (basic)-0.38-0.59
EPS (diluted)-0.38-0.62
Weighted avg. shares (diluted)919.86M700.44M
Balance sheet
Cash & equivalents$88.33M$143.43M
Short-term investments$154.48M$6.38M
Receivables$42.57M$2.36M
Inventory$910,000$8.27M
Current assets$314.88M$184.59M
PP&E, net$114.26M$137.09M
Goodwill$910,000$910,000
Intangibles$12.99M$14.53M
Total assets$501.90M$382.93M
Current liabilities$61.75M$54.94M
Short-term debt$1.75M$1.25M
Total liabilities$1.00B$871.06M
Shareholders' equity-$500.47M-$489.10M
Shares outstanding1.01B852.90M
Cash flow statement
Operating cash flow-$304.94M-$391.24M
Capital expenditure$3.85M$6.89M
Free cash flow-$308.78M-$398.12M
Investing cash flow-$149.80M-$12.25M
Financing cash flow$400.24M$281.63M
Depreciation & amortization$15.53M$17.55M
Stock-based compensation$36.81M$34.43M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.